Sign Up
OverviewAPI
The article highlights the increasing focus on targeting CD70 for cancer treatment through monoclonal antibodies, ADCs, and cell therapies. Companies globally, including argenx, OncoVerity, and Nkarta, are actively exploring CD70 interference strategies. Ongoing clinical trials, especially CAR-T cell therapies, are at the forefront. Both the US and China are heavily involved in developing CD70-targeted therapies, with notable companies like Allogene Therapeutics, CRISPR Therapeutics, Yake Biotechnology, and UTC Therapeutics leading the way.

Ask a question